Last reviewed · How we verify

NCT06965101: RESONATE

To Determine Whether it is Feasible to Treat Patients Requiring Urgent Radiotherapy Diagnosed With Metastatic Cord Compression (MSCC) on the Magnetic Resonance Linear Accelerator (MRL) in a Single Appointment and Compare it to the Standard of Care Radiotherapy Pathway

Recruiting now NA Last updated 2 December 2025
What this trial tests

NA trial testing Radiotherapy to the spine in a single appointment in Metastatic Spinal Cord Compression in 72 participants. Currently enrolling.

Timeline
4 November 2025
Primary endpoint
4 November 2027
4 November 2028

Quick facts

Lead sponsorThe Christie NHS Foundation Trust
PhaseNA
StatusRecruiting now
Study typeINTERVENTIONAL
Allocationnon randomized
Designparallel
Maskingnone
Primary purposesupportive care
Enrollment72
Start date4 November 2025
Primary completion4 November 2027
Estimated completion4 November 2028
Sites1 location across United Kingdom

Drugs / interventions tested

Conditions studied

Sponsor

The Christie NHS Foundation Trust

Who can join

18 and older, any sex, with Metastatic Spinal Cord Compression. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this clinical trial is to understand whether the Magnetic Resonance Linear Accelerator (MRL) could expedite Radiotherapy treatment for Metastatic Cord Compression (MSCC) by removing the need for a planning CT (pCT) scan prior to treatment. Radiotherapy will be delivered in one appointment on the MRL and compared to the standard of care of two appointments: a CT scan and a Radiotherapy appointment. The main questions it aims to answer are: * Can the MRL deliver successful treatment of MSCC in a single 1-hour appointment? * Can the MRL treat participants within 24 hours from the doctor's decision to treat? * Did it take less time from consent to completion of treatment when patients were treated on the MRL? * Do the questionnaire scores reflect satisfaction with treatment on the MRL? Researchers will compare treatment on the MRL in one appointment to a group receiving standard of care radiotherapy in two appointments. Participants in both groups will receive the same prescription of 8Gray (Gy) in one treatment (fraction) delivered with one posterior-anterior beam as per our department policies and national standards. Participants will be asked to complete an optional questionnaire prior to treatment to monitor the diversity of the study population. This questionnaire is anonymised, no personal data that could identify a participant is collected on this questionnaire. After treatment participants will be asked to complete an experience questionnaire, to assess treatment experience. Once the questionnaire is complete active participation in the trial is no longer needed, researchers will monitor participants notes for up to 12 months after treatment to record participant well being and function.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Metastatic Spinal Cord Compression

Currently open trials in the same condition.

Other The Christie NHS Foundation Trust trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06965101.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing